Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Trading 07-27 15:52:56 EDT

8.71

-0.99

-10.21%

High9.15	Low7.37	Vol7.63M
Open8.69	D1 Closing9.70	Amplitude18.35%
Mkt Cap731.16M	Tradable Cap520.09M	Total Shares83.95M
T/O65.03M	T/O Rate12.77%	Tradable Shares59.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":8.71,"timestamp":1785181972125,"preClose":9.7,"halted":0,"volume":7627529,"delay":0,"changeRate":-0.10206185567010294,"floatShares":59711800,"shares":83945161,"eps":-3.382838,"marketStatus":"Trading","change":-0.99,"latestTime":"07-27 15:52:56 EDT","open":8.685,"high":9.15,"low":7.37,"amount":65026202.60327101,"amplitude":0.183505,"askPrice":8.71,"askSize":733,"bidPrice":8.7,"bidSize":303,"shortable":0,"etf":0,"ttmEps":-3.382838,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785182400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":9.7,"preHourTrading":{"tag":"盘前","latestPrice":8.7,"preClose":9.7,"latestTime":"09:29 EDT","volume":106596,"amount":945129.383352,"timestamp":1785158999999,"change":-1,"changeRate":-0.103093,"amplitude":0.16701},"postHourTrading":{"tag":"盘后","latestPrice":9.819,"preClose":9.7,"latestTime":"19:41 EDT","volume":542093,"amount":5258340.0658,"timestamp":1784936494509,"change":0.119,"changeRate":0.012268,"amplitude":0.018072},"volumeRatio":2.278352,"optionData":{"bulkOrders":[{"symbol":"REPL","call":true,"expireDate":1785470400000,"strike":"15.0","timestamp":1785166652431,"price":0.5,"volume":3000,"amount":150000,"type":"-"},{"symbol":"REPL","call":true,"expireDate":1785470400000,"strike":"9.5","timestamp":1785166652431,"price":2,"volume":3000,"amount":600000,"type":"+"}]},"impliedVol":4.0422,"impliedVolPercentile":0.9641},"requestUrl":"/m/hq/s/REPL/","defaultTab":"news","newsList":[{"id":"2654812049","title":"Replimune Group put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2654812049","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654812049?lang=en_us&edition=fundamental","pubTime":"2026-07-27 23:00","pubTimestamp":1785164409,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Replimune (REPL) Group with 6,933 puts trading, or 3x expected. Most active are 8/7 weekly 8.5 calls and 8/28 weekly 20 puts,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652140162","title":"Replimune Group put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2652140162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652140162?lang=en_us&edition=fundamental","pubTime":"2026-07-20 23:15","pubTimestamp":1784560507,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Replimune (REPL) Group with 3,199 puts trading, or 1.5x expected. Most active are Sep-26 18 puts and Aug-26 8 puts, with tota...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651142889","title":"Replimune Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2651142889","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651142889?lang=en_us&edition=fundamental","pubTime":"2026-07-14 05:21","pubTimestamp":1783977696,"startTime":"0","endTime":"0","summary":"Replimune announces annual shareholder meetingReplimune will hold its 2026 annual shareholder meeting virtually on Sept. 15, 2026.Shareholders will vote on a charter amendment to double authorized com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL2tRgmw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649932757","title":"Replimune Group put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2649932757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649932757?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:20","pubTimestamp":1783452010,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Replimune (REPL) Group with 5,913 puts trading, or 3x expected. Most active are 8/14 weekly 8 puts and 8/7 weekly 8 puts, wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647593855","title":"Replimune Group is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2647593855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647593855?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:01","pubTimestamp":1782824460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:01 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553289","title":"Replimune price target raised to $9 from $6 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553289?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:50","pubTimestamp":1782820226,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Replimune (REPL) to $9 from $6 and keeps a Neutral rating on the shares. The firm notes the company repor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-9-from-6-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-9-from-6-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530859","title":"Replimune Group Inc : Bmo Raises to Outperform from Underperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530859?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:50","pubTimestamp":1782816651,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647303054","title":"Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2647303054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647303054?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:55","pubTimestamp":1782748543,"startTime":"0","endTime":"0","summary":"Replimune (REPL) has an average rating of hold and mean price target of $7.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647330358","title":"Replimune Group put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2647330358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647330358?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:15","pubTimestamp":1782746109,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Replimune (REPL) Group with 1,899 puts trading, or 1.4x expected. Most active are Aug-26 7 puts and Aug-26 15 calls, with tot...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374518","title":"Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374518","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647374518?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:52","pubTimestamp":1782737550,"startTime":"0","endTime":"0","summary":"Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.71) by 7.04 percent. This is a 7.32 percent increase over losses of $(0.82) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://www.benzinga.com/news/earnings/26/06/60154266/replimune-group-q4-eps-0-76-misses-0-71-estimate","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60154266/replimune-group-q4-eps-0-76-misses-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371279","title":"Replimune Group Inc Reports Results for the Quarter Ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371279","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371279?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:37","pubTimestamp":1782736650,"startTime":"0","endTime":"0","summary":"Replimune Group Inc reports results for the quarter ended March 31 - Earnings SummaryReplimune Group IncREPL.OQreported a quarterly adjusted loss of 76 cents per share for the quarter ended March 31, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL8N4310ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647437160","title":"Replimune's Fiscal Q4 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2647437160","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647437160?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:27","pubTimestamp":1782736058,"startTime":"0","endTime":"0","summary":"Replimune Group  reported a fiscal Q4 net loss Wednesday of $73.7 million, narrowing from a net loss of $74.1 million a year earlier.Analysts polled by FactSet expected a net loss of $63.9 million.As of March 31, the company said it had $268.9 million in cash, cash equivalents and short-term investments, which it said will fund operations into Q1 2027.Shares of the company were down 2.8% in Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647777379","title":"Earnings Flash (REPL) Replimune Posts Fiscal 2026 Net Loss $3.38 a Share, vs. FactSet Est of $3.27 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2647777379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647777379?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:09","pubTimestamp":1782734963,"startTime":"0","endTime":"0","summary":"Earnings Flash (REPL) Replimune Posts Fiscal 2026 Net Loss $3.38 a Share, vs. FactSet Est of $3.27 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647293379","title":"Replimune FY26 Net Loss Widens to $313.94 Million; R&D Expenses Rise to $221.18 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647293379","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647293379?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:03","pubTimestamp":1782734609,"startTime":"0","endTime":"0","summary":"Replimune FY26 net loss widens to $313.94 million; R&D expenses rise to $221.18 millionReplimune fiscal year ended March 31, 2026 net loss widened to USD 313.94 million; loss per share widened to USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL2hqk3p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","BK4112","SG9999014005.SGD","BK4139","LU2210150020.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","REPL","LU2095319765.USD","IE00BGHQF748.EUR","BK4588","NDAQ","IE00BN0W2V16.EUR","SG9999014039.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","LU0314104364.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379654","title":"Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379654?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA930WZ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379100","title":"Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379100?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:50","pubTimestamp":1782733832,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR). Repli...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-replimune-group-repl-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-replimune-group-repl-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","MNPR","REPL","BK4581","HCSG","LABU","XLV","BK4588","LU0128526141.USD","XBI","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646702366","title":"Replimune Group Inc : JP Morgan Raises to Overweight from Neutral; Raises Target Price to $17 from $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2646702366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646702366?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:28","pubTimestamp":1782487687,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42Y0VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646350431","title":"Replimune Slips as FDA Accepts Skin Cancer Drug Review, but Advisory Panel Adds Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646350431?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:17","pubTimestamp":1782479878,"startTime":"0","endTime":"0","summary":"BUZZ-Replimune slips as FDA accepts skin cancer drug review, but advisory panel adds risk** Shares of ReplimuneREPL.Ofall 4.7% to $10.61 premarket** Replimune says the U.S. FDA has accepted co's resub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU2242646821.SGD","LU1430594728.SGD","LU1032466523.USD","LU0096364046.USD","LU2596442595.SGD","BK4007","LU1670710661.SGD","LU0225284248.USD","IE00B2B36J28.USD","LU0432979614.USD","REPL","LU1074936037.SGD","BK4588","IE00BSNM7G36.USD","BK4534","LU0456855351.SGD","LU1571399168.USD","LU0306806265.USD","IE00BJT1NW94.SGD","LU2242652126.USD","LU1670711123.USD","LU2125154935.USD","LU1323610961.USD","LU0225771236.USD","LU1868837300.USD","LU1093756168.USD","LU0985481810.HKD","LU2360032135.SGD","LU1868837136.USD","IE00BJJMRZ35.SGD","LU2125154778.USD","LU0114720955.EUR","LU2133065610.SGD","BK4532","IE0009355771.USD","LU0882574055.USD","BMY","BK4581","LU0061475181.USD","IE0002141913.USD","LU1718418525.SGD","IE00BFTCPJ56.SGD","LU1883839398.USD","IE00BFXG1179.USD","LU1868836914.USD","LU0868494617.USD","LU1670711040.USD","LU1983299246.USD","LU0237698245.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646235252","title":"Replimune Says FDA Accepts RP1 Melanoma BLA Resubmission for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2646235252","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646235252?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:01","pubTimestamp":1782475267,"startTime":"0","endTime":"0","summary":"Replimune says FDA accepts RP1 melanoma BLA resubmission for reviewReplimune’s FDA accepted for review the resubmitted BLA for RP1 with nivolumab in advanced melanoma.Agency classified the filing as a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLsmYyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00BN0W2W23.USD","REPL","BK4112","BK4139","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646525563","title":"Replimune Group - FDA Sets August 2, 2026 Goal Date for Rp1 Bla Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2646525563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646525563?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:00","pubTimestamp":1782475200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA4XW62Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com;ir.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0518},{"period":"1month","weight":-0.1393},{"period":"3month","weight":3.0083},{"period":"6month","weight":0.2581},{"period":"1year","weight":2.129},{"period":"ytd","weight":-0.0021}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.229422},{"month":7,"riseRate":0.25,"avgChangeRate":-0.092852},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}